title: [Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
abstract: OBJECTIVE
  To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX) or carboplatin (CBP) on the proliferation of triple-negative breast cancer cell line MDA-MB-231 and to investigate whether PARP inhibitor AG014699 combined with chemotherapy could play a synergistic antitumor effect.
  
  
  METHODS
  MDA-MB-231 cells were treated by PARP inhibitor AG014699 alone or combination with DTX or CBP. Cell proliferation was measured by cell counting kit-8 assay. The combined effect was evaluated by q value less than 0.85, in the range of 0.85 and 1.15, more than 1.15, which respectively meant that the combined effect of the drugs was antagonistic, additive, and synergistic.
  
  
  RESULTS
  Treatment with PARP inhibitor AG014699, DTX, or CBP alone inhibited the proliferation, induced apoptosis and blocked the cell cycle. The cell viability of AG014699 (10 µmol/L) combined with DTX (10(-8), 10(-7), 10(-6), 10(-5) mol/L) or CBP (10(-5), 10(-4) mol/L) were lower than that of the drug used alone, and q value was between 0.85 and 1.15, suggesting the combined effect was additive. The cell viability of AG014699 (10 µmol/L) combined with CBP (10(-3) mol/L) was lower than that of the drug used alone, and q value was more than 1.15, suggesting the combined effect was synergetic. A combination of PARP inhibitor AG014699 and DTX or CBP promoted apoptosis and increased the proportion of G2/M stage cells.
  
  
  CONCLUSIONS
  PARP inhibitor AG014699 combined with DTX or CBP can remarkably inhibit MDA-MB-231 cell proliferation, showing additive or synergistic antitumor effects.
authors.affiliation: Department of Clinical Oncology,Qilu Hospital of Shandong University,Jinan 250012,China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Sun
authors.affiliation: Department of Clinical Oncology,Qilu Hospital of Shandong University,Jinan 250012,China.
authors.forename: Huan
authors.initials: H
authors.lastname: Ding
authors.affiliation: Medical College,Zhejiang University,Hangzhou 310058,China.
authors.forename: Xiao-qing
authors.initials: XQ
authors.lastname: Li
authors.affiliation: Department of Clinical Oncology,Qilu Hospital of Shandong University,Jinan 250012,China.
authors.forename: Li
authors.initials: L
authors.lastname: Li
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D017209:Apoptosis / Q000187:drug effects; D016190:Carboplatin / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D064726:Triple Negative Breast Neoplasms / Q000473:pathology*
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; C531549:rucaparib; D016190:Carboplatin